What Creatv Bio does

Creatv Bio is a privately held biotechnology company operating as a division of Creatv MicroTech, Inc., headquartered in Rockville, Maryland. The company develops and commercializes a blood-based liquid biopsy platform built around its proprietary CellSieve microfilter technology, which physically isolates cancer-associated cells including circulating tumor cells (CTCs) and Cancer-Associated Macrophage-Like Cells (CAMLs) from a 7 mL whole blood sample. Its flagship LifeTracDx test serves as a biomarker for cancer screening, treatment response monitoring within 30 days, recurrence detection, cancer aggressiveness assessment, and blood-based companion diagnostics across drug targets including PD-L1, HER2, CCR5, CXCR4, and VEGFR1-2.

Creatv Bio monetizes primarily through professional services revenue from biopharmaceutical and biotech partners conducting oncology clinical trials, with named engagements including Neovia Oncology (NEV-801 multiple drug resistance studies) and CytoDyn (Phase II leronlimab colorectal cancer trial). The company opened a CLIA-certified laboratory in May 2026 to directly perform diagnostic testing for biopharma clients. A secondary revenue stream comprises ongoing patient monitoring services on a recurring basis. The company's commercial model is enterprise-direct, relying on scientific publications, conference presentations at AACR, ASCO, SABCS, and ESMO, and direct partnership engagement rather than traditional consumer or physician channel marketing.

The company holds 18 US and international patents with 57 issued, plus a Japanese patent covering cancer screening technology. Its founder, Cha-Mei Tang, has 163 journal publications and book chapters, and the firm has reported CAML detection in over 30 cancer types with detection rates exceeding 80% in Stages I/II for breast, prostate, lung, and colorectal cancers. Capital formation to date has come entirely from non-dilutive government grants (DARPA 2014, NIH/NCI SBIR 2017, DoD 2018) rather than priced equity rounds.

Name

Creatv Bio

Legal name

Creatv MicroTech, Inc.

Website

https://creatvbio.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Creatv Bio is a privately held Maryland-based liquid biopsy company that uses proprietary CellSieve microfilters to isolate cancer-associated cells from blood, offering biomarker and companion diagnostic services primarily to biopharmaceutical partners conducting oncology clinical trials.

Ownership category

akta.pro rank

Product category

Cancer Diagnostics

NAICS

Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE)

akta.pro secondary industries

Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• Liquid biopsy diagnostics
• Cancer biomarker analysis
• Companion diagnostics services
• Clinical trial biomarkers
• Circulating tumor cells

Headquarters

HQ city

Rockville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Clinical Trial Services: Laboratory testing services provided to biopharmaceutical companies for clinical trial biomarker analysis and patient stratification using the LifeTracDx liquid biopsy test
2. Diagnostic Testing Services: Ongoing monitoring services for cancer patients including treatment response monitoring, residual disease detection, and recurrence monitoring through serial blood testing

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

Creatv Bio develops and delivers the LifeTracDx liquid biopsy blood test, which uses proprietary CellSieve microfilters to isolate cancer-associated cells (CTCs and CAMLs) from a 7 mL whole blood sample for cancer screening, treatment response monitoring, and companion diagnostics. The company operates a CLIA-certified laboratory offering BioPharma services that include clinical trial biomarker analysis, patient stratification, and drug target validation for pharmaceutical partners.

Product overview

Creatv Bio, a division of Creatv MicroTech, Inc., offers a portfolio of cancer diagnostic products centered on its proprietary LifeTracDx liquid biopsy platform. The core offering combines CellSieve microfilter technology with blood-based biomarker analysis to detect and monitor cancer. Key products include the LifeTracDx blood test, CellSieve microfilters, and specialized diagnostic services for cancer screening, treatment response monitoring, cancer aggressiveness determination, and companion diagnostics. The company provides BioPharma Services supporting clinical trials and drug development for pharmaceutical partners.

Differentiator

Problem solved

Functional benefit

Brands

• LifeTracDx: Liquid biopsy blood test for cancer detection and monitoring
• CellSieve

Products and services

• LifeTracDx Liquid Biopsy Test

Quantifiable outcome

• Detection rates over 80% in Stages I/II for major cancers (breast, prostate, lung, colorectal)
• +2 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• Neovia Oncology LLCcoreStrategic or Co-development Partner · 2 June 2026Strategic partnership to study multiple drug resistance (MDR) in solid tumors, focusing on Neovia's NEV-801 drug candidate for advanced cancer patients in late lines of therapy. The collaboration uses Creatv's LifeTracDx liquid biopsy blood test to generate translational and biomarker data for patient stratification and treatment response monitoring.
• Multiple Pharmaceutical Research PartnersminorStrategic or Co-development Partner · 20 May 2026Multiple clinical collaborations with pharmaceutical research partners including studies presented at AACR 2026 showing monitoring of CTCs, CAMLs, and PD-L1 expression to improve disease risk stratification and predict responses to immune checkpoint inhibitors.
• CytoDyncoreStrategic or Co-development Partner · 3 March 2026Collaboration using Creatv's LifeTracDx liquid biopsy PD-L1 test as exploratory biomarker in CytoDyn's Phase II clinical trial for relapsed/refractory metastatic colorectal cancer. The trial evaluates leronlimab (CCR5-specific monoclonal antibody) in combination with TAS-102 and bevacizumab, enrolling 60 patients with objective response rate as primary endpoint.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Personalis: Personalis develops ultrasensitive ctDNA-based MRD and immunotherapy monitoring assays (NeXT Personal) for pharma and oncology applications. It is an emerging liquid biopsy peer competing for biomarker-guided trial partnerships.
• Tempus AI: Tempus combines multi-omic sequencing, AI, and a CLIA lab to provide biomarker discovery and clinical trial services to pharma. It is an emerging peer pursuing similar biopharma biomarker contracts through its own proprietary testing platform.
• ANGLE plc: ANGLE plc has developed the Parsortix microfluidic CTC isolation system for cancer liquid biopsy, including companion diagnostic applications with pharma. It is an emerging peer pursuing CTC-based biomarker services analogous to Creatv's CellSieve platform.

Direct peers

• Natera: Natera develops cell-free DNA and molecular testing for oncology, including Signatera for MRD monitoring. Its blood-based oncology testing business directly competes with Creatv's LifeTracDx in treatment response and recurrence monitoring use cases.
• Menarini Silicon Biosystems: Menarini Silicon Biosystems markets the CELLSEARCH platform, the established clinical standard for enumerating circulating tumor cells from blood. It is a direct technology peer in CTC-based liquid biopsy isolation used for oncology clinical trials.
• NeoGenomics: NeoGenomics operates a global oncology-focused clinical laboratory network serving community hospitals, oncology practices, and pharma clients with biomarker and clinical trial testing. It is a comparable oncology CRO/lab services peer for Creatv Bio's biopharma services offering.
• Guardant Health: Guardant Health is a leading liquid biopsy company offering blood-based ctDNA assays for oncology clinical trials, therapy selection, and recurrence monitoring. It is the most direct competitor to Creatv Bio in serving pharma biomarker needs and oncology testing services.

Others

• Bio-Techne: Bio-Techne provides research-use biomarker reagents, immunoassay kits, and exosome diagnostics that supply the broader cancer diagnostics and biomarker ecosystem. It is an adjacent industry peer and potential technology enabler rather than a direct clinical services competitor.

Broad incumbents

• Foundation Medicine: Foundation Medicine (a Roche subsidiary) provides comprehensive genomic profiling of solid tumors and biopharma CDx services. It competes with Creatv Bio for companion diagnostic and clinical trial biomarker partnerships but operates at significantly greater scale and breadth.
• Exact Sciences: Exact Sciences is a major cancer diagnostics company offering Cologuard and Oncotype DX products, with growing presence in liquid biopsy through its Cologuard Plus and Oncodetect MRD assay. It represents a broad incumbent competing in cancer screening and recurrence detection.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Creatv Bio